Fabtech Technologies Ltd
Incorporated in 2018, Fabtech Technologies Ltd is a biopharma engineering company.[1]
- Market Cap ₹ 1,066 Cr.
- Current Price ₹ 240
- High / Low ₹ 263 / 173
- Stock P/E 29.2
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 19.6 %
- ROE 16.7 %
- Face Value ₹ 10.0
Pros
Cons
- Earnings include an other income of Rs.30.5 Cr.
- Company has high debtors of 190 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology
Part of BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 133 | 121 | 257 | 194 | 225 | 236 | |
| 119 | 110 | 225 | 169 | 190 | 210 | |
| Operating Profit | 14 | 11 | 32 | 25 | 35 | 27 |
| OPM % | 11% | 9% | 13% | 13% | 16% | 11% |
| 5 | 2 | 2 | 6 | 4 | 30 | |
| Interest | 2 | 2 | 3 | 5 | 3 | 3 |
| Depreciation | 0 | 0 | 1 | 2 | 2 | 2 |
| Profit before tax | 16 | 11 | 31 | 24 | 35 | 52 |
| Tax % | 27% | 29% | 27% | 27% | 25% | 26% |
| 12 | 8 | 23 | 18 | 26 | 38 | |
| EPS in Rs | 11,720.00 | 7,630.00 | 81.23 | 63.46 | 89.04 | 11.85 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | -3% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 1% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 21% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 3 | 3 | 3 | 32 | 32 |
| Reserves | 37 | 44 | 64 | 79 | 121 | 125 | 137 |
| 1 | 9 | 19 | 34 | 11 | 62 | 42 | |
| 84 | 70 | 83 | 91 | 113 | 120 | 163 | |
| Total Liabilities | 122 | 124 | 169 | 207 | 248 | 340 | 375 |
| 2 | 2 | 3 | 4 | 5 | 55 | 55 | |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | 11 | 5 | 14 | 14 | 36 | 28 | 24 |
| 109 | 116 | 152 | 190 | 207 | 258 | 295 | |
| Total Assets | 122 | 124 | 169 | 207 | 248 | 340 | 375 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 27 | -9 | -5 | -16 | 60 | -53 | |
| -20 | 4 | -9 | 2 | -28 | 12 | |
| 5 | 6 | 10 | 12 | -14 | 16 | |
| Net Cash Flow | 13 | 1 | -4 | -2 | 18 | -24 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 123 | 187 | 153 | 190 |
| Inventory Days | 22 | 39 | 17 | 69 | 49 | 45 |
| Days Payable | 82 | 150 | 136 | 215 | 173 | 208 |
| Cash Conversion Cycle | 51 | 25 | 5 | 41 | 29 | 27 |
| Working Capital Days | -19 | 15 | 37 | 65 | 47 | 61 |
| ROCE % | 27% | 49% | 29% | 30% | 20% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12h - Newspaper publication under Regulation 30 and 47 of the SEBI (LODR) Regulations, 2015 regarding Financial Results for the quarter ended June 30, 2025 and for …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - KP Group and Fabtech sign MoU to develop renewable-powered pharma, biotech, healthcare infrastructure across India, Middle East, Africa.
- Unaudited Standalone And Consolidated Financials Results Of The Company For The Quarter Ended June 30, 2025 2d
- Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2025 2d
-
Board Meeting Outcome for Outcome Of Board Meeting- Disclosure Under Regulation 30 And 33 Of The SEBI (LODR) Regulations, 2015
2d - Approved unaudited standalone and consolidated results for quarter June 30 and quarter/half-year Sept 30, 2025; limited review enclosed.
Business Profile[1]
Fabtech provides end-to-end turnkey pharma plant solutions covering design, engineering, procurement, installation, and regulatory validation, while also offering standalone execution services like equipment supply and installation for clients with their own designs.